Novo Nordisk AS Newswire (Page 6)

Novo Nordisk AS Newswire (Page 6)

Comprehensive Real-Time News Feed for Novo Nordisk AS. (Page 6)

Results 101 - 120 of 1,279 in Novo Nordisk AS

  1. Novo Nordisk A/S (NVO) Upgraded at Zacks Investment ResearchRead the original story w/Photo

    May 8, 2016 | Daily Political

    They currently have $63.00 price target on the stock. According to Zacks, "Novo Nordisk's first-quarter results were mixed with the company beating on the bottom line but slightly missing on the top line estimates.

    Comment?

  2. Beyond Obamacare: Stopping Corporations from Making People SickRead the original story w/Photo

    May 6, 2016 | The American Prospect

    But not much attention has been given to going beyond the Affordable Care Act to take on the root cause of our nation's most serious health problems: a corporate system that profits by sickening people. Yes, the ACA dramatically improved American health-care access-about 20 million Americans have gained insurance coverage, and nearly 71 million now enjoy expanded access to free preventive services through their private plans. 1 comment

  3. Novo Nordisk A/S Injecting Future SalesRead the original story w/Photo

    May 5, 2016 | Fox News

    Novo Nordisk released earnings on Friday, with sales hitting the upper end of the drugmaker's 2016 guidance as the company highlighted recent positive clinical trial results. Victoza was the biggest contributor to growth with an increase of 15% in local currencies and 16% in Danish kroner even in the face of competition from Eli Lilly 's competing GLP-1 drug, Trulicity.

    Comment?

  4. Novo Nordisk A/S Injecting Future SalesRead the original story w/Photo

    May 5, 2016 | The Motley Fool

    Victoza was the biggest contributor to growth with an increase of 15% in local currencies and 16% in Danish kroner even in the face of competition from Eli Lilly 's Sales of Novo Nordisk's newest insulin are off to a good start, increasing 117% in local currencies, but it's building from a small base with just 1.4% of the U.S. market share after launching stateside in January. Earnings were down year over year because of the partial divestment of its IT services business.

    Comment?

  5. Novo Nordisk A/S (NVO) to Post FY2016 Earnings of $2.28 Per Share, Leerink Partner ForecastsRead the original story w/Photo

    May 5, 2016 | Daily Political

    Stock analysts at Leerink Partner lifted their FY2016 EPS estimates for Novo Nordisk A/S in a note issued to investors on Monday, according to Zacks Investment Research . Leerink Partner analyst S. Fernandez now forecasts that the brokerage will earn $2.28 per share for the year, up from their prior estimate of $2.24.

    Comment?

  6. Q2 2016 Earnings Estimate for Novo Nordisk A/S (NVO) Issued By Leerink PartnerRead the original story w/Photo

    May 4, 2016 | Daily Political

    Equities research analysts at Leerink Partner lifted their Q2 2016 EPS estimates for shares of Novo Nordisk A/S in a research report issued to clients and investors on Monday, Zacks Investment Research reports. Leerink Partner analyst S. Fernandez now forecasts that the firm will post earnings per share of $0.56 for the quarter, up from their prior estimate of $0.52.

    Comment?

  7. IMF warns Denmark of risk for exports if Britain quits EURead the original story

    May 4, 2016 | Yahoo!

    Denmark's exports to the UK would probably suffer if the British vote to leave the European Union at referendum in June, the International Monetary Fund said on Wednesday. Great Britain is Denmark's third-largest market after Germany and Sweden, with exporters such as dairy group Arla, insulin maker Novo Nordisk "If a Brexit would happen that would likely affect trade flows, which are important for Denmark, and it would have significantly effect in international financial markets", David Hofman, the head of an IMF delegation said.

    Comment?

  8. Bright Horizons Family Solutions (BFAM) David H. Lissy on Q1 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    May 3, 2016 | Seeking Alpha

    Greetings and welcome to the Bright Horizons Family Solutions First Quarter 2016 Earnings Conference Call. At this time, all participants are in a listen-only mode.

    Comment?

  9. Novo Nordisk A/S (NVO) Rating Increased to Buy at Zacks Investment ResearchRead the original story w/Photo

    May 3, 2016 | AmericanBankingNews.com

    The brokerage presently has a $63.00 price target on the stock. Zacks Investment Research 's target price would suggest a potential upside of 12.80% from the company's current price.

    Comment?

  10. Novo Nordisk A/S (NVO) Upgraded by Zacks Investment Research to BuyRead the original story w/Photo

    May 3, 2016 | AmericanBankingNews.com

    The firm currently has a $63.00 price target on the stock. Zacks Investment Research 's price objective would indicate a potential upside of 12.80% from the company's previous close.

    Comment?

  11. Trading in Novo Nordisk shares by board members, executives and associated persons on 2 May 2016Read the original story w/Photo

    May 3, 2016 | GlobeNewswire

    BagsvA rd, Denmark, 3 May 2016 In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

    Comment?

  12. Novo Nordisk: Earnings Are In, When Will This Stock Lift Off?Read the original story w/Photo

    May 2, 2016 | Seeking Alpha

    The stock seems stuck, but if Novo Nordisk hits gold in their pipeline, the share price will adjust and go above $60. Novo Nordisk , as I pointed out in my earlier articles , is one significant powerhouse which can't be ignored by long-term investors.

    Comment?

  13. Novo Nordisk A/S (NVO) Posts Earnings Results, Beats Estimates By $0.04 EPSRead the original story w/Photo

    May 2, 2016 | Daily Political

    Novo Nordisk A/S posted its quarterly earnings results on Friday. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.53 by $0.04, Market Beat.com reports.

    Comment?

  14. Vivus - Qsymia Sales Continue To Be UnderwhelmingRead the original story w/Photo

    May 2, 2016 | Seeking Alpha

    Vivus is seeing more of the same from the sales of Qsymia. Sales of the anti-obesity drug have been carrying a small downward bias all year, and Q2 of 2016 is actually pacing behind Q1.

    Comment?

  15. Novo Nordisk A/S (NVO) Downgraded by Zacks Investment ResearchRead the original story w/Photo

    May 2, 2016 | AmericanBankingNews.com

    According to Zacks, "Novo Nordisk's first-quarter results were mixed with the company beating on the bottom line but slightly missing on the top line estimates. Revenue growth was driven by strong sales in the U.S. and international operations.

    Comment?

  16. Use of Healthcare Services Following Severe Hypoglycemia in Patients...Read the original story

    May 2, 2016 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Severe hypoglycemia is a burden for both patients and the healthcare system payer alike.

    Comment?

  17. Novo Nordisk's (NVO) CEO Lars Rebien Sorensen on Q1 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    Apr 29, 2016 | Seeking Alpha

    Welcome to the first quarter 2016 Novo Nordisk earnings conference call. For your information, today's conference is being recorded.

    Comment?

  18. Europe close: Risk appetite falls ahead of long weekend, US jobs reportRead the original story w/Photo

    Apr 29, 2016 | Live Charts

    European stocks fell on Friday, ahead of the long weekend and next FridayA s all-important US jobs report, despite better than expected readings on economic growth and unemployment. Nevertheless, the euro area slipped further into deflation in April, according to the latest figures from Eurostat.

    Comment?

  19. Novo Nordisk says US launch 'encouraging' as profit dropsRead the original story w/Photo

    Apr 29, 2016 | PhysOrg Weblog

    The world's largest maker of diabetes treatments, Novo Nordisk, said on Friday that the US launch of ultra-long acting insulin Tresiba had been "encouraging" as it reported a drop in first quarter profit. Net profit fell four percent to 9.46 billion kroner , reflecting one-off gains last year from the spinoff of its IT services arm NNIT, but came in ahead of a Bloomberg analyst consensus of 9.15 billion kroner.

    Comment?

  20. Europe midday: Stocks drop as investors wade through earnings, dataRead the original story w/Photo

    Apr 29, 2016 | Live Charts

    European stocks fell on Friday, as investors weighed up encouraging news on Eurozone growth and employment against evidence the bloc was falling further into deflation, amid a deluge of corporate news. At midday, the benchmark Stoxx Europe 600 index was down 1.3%, Germanys' DAX was off 1.4% and France's CAC 40 was 1.7% weaker.

    Comment?